Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

NCT04908475 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

352

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: Risankizumab
DRUG: Apremilast

Sponsor

AbbVie